Protective Effect of Metformin on Myocardial Injury in Metabolic Syndrome Patients following Percutaneous Coronary Intervention

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Cardiology

• Publication date

  2013-12-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000355574PMID 24335026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose.

  2013cited by this paper
• Metformin action on AMP‐activated protein kinase: a translational research approach to understanding a potential new therapeutic target

  2010cited by this paper
• Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor

  2009cited by this paper
• Coronary microembolization: from bedside to bench and back to bedside.

  2009cited by this paper
• Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance.

  2008cited by this paper
• Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening

  2008cited by this paper
• Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated Signaling

  2008cited by this paper
• Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration.

  2008cited by this paper
• Impact of metabolic syndrome on tissue characteristics of angiographically mild to moderate coronary lesions integrated backscatter intravascular ultrasound study.

  2007cited by this paper
• Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.

  2007cited by this paper
• Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction.

  2005cited by this paper
• Ischaemic preconditioning: from molecular characterisation to clinical application--part I.

  2004cited by this paper
• Ischaemic preconditioning: from molecular characterisation to clinical application--part II.

  2004cited by this paper
• Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention.

  2003cited by this paper
• Frequency and long-term impact of myonecrosis after coronary stenting.

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary

  2001cited by this paper
• Adenosine, adenosine receptors and myocardial protection: an updated overview.

  2001cited by this paper
• Myonecrosis after revascularization procedures.

  1998cited by this paper
• Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions.

  1996cited by this paper
• Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics.

  1989cited by this paper

• İNSÜLİN DİRENCİ VE ALZHEİMER HASTALIĞI ARASINDAKİ PATOJENİK BAĞLANTI: FARMAKOLOJİK MÜDAHALELER

  2025cites this paper
• Metformin Preconditioning Augments Cardiac Perfusion and Performance in a Large Animal Model of Chronic Coronary Artery Disease

  2024cites this paper
• Investigation of Anti-inflammatory, Antioxidative, and Cardioprotective Effects of Combined Metformin and Exercise in Rats

  2024cites this paper
• Metabolic Complications of Glucocorticoids - Prevention by Metformin.

  2023cites this paper
• Insulin resistance in Alzheimer's disease: The genetics and metabolomics links.

  2022cites this paper
• The impact of metformin on cardiac troponin-I and ST resolution in patients with ST elevation myocardial infarction undergoing thrombolytic therapy

  2022influential citation
• Rosmarinic Acid Ameliorates Pulmonary Ischemia/Reperfusion Injury by Activating the PI3K/Akt Signaling Pathway

  2022cites this paper
• Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK‐dependent mechanisms

  2022cites this paper
• The metabolic signatures of cardiometabolic diseases: Does the shared metabotype offer new therapeutic targets?

  2021cites this paper
• Metabolomics applications in coronary artery disease personalized medicine.

  2021cites this paper
• The metabolic signatures of cardiometabolic diseases: Does the shared metabotype offer new therapeutic targets?

  2021cites this paper
• Impact of the Main Cardiovascular Risk Factors on Plasma Extracellular Vesicles and Their Influence on the Heart’s Vulnerability to Ischemia-Reperfusion Injury

  2021cites this paper
• Metformin relieves H/R-induced cardiomyocyte injury through miR-19a/ACSL axis - possible therapeutic target for myocardial I/R injury.

  2021cites this paper
• AMP-activated protein kinase: An attractive therapeutic target for ischemia-reperfusion injury.

  2020cites this paper
• Drug repurposing in cardiovascular diseases: opportunity or hopeless dream?

  2020cites this paper
• Treatment with metformin prevents myocardial ischemia–reperfusion injury via STEAP4 signaling pathway

  2019cites this paper
• Effects of metformin on the heart with ischaemia-reperfusion injury: Evidence of its benefits from in vitro, in vivo and clinical reports.

  2019cites this paper
• Metformin and kidney protection; a letter to editor on recent findings

  2019cites this paper
• Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis

  2019cites this paper
• The efficacy of metformin treatment for myocardial infarction: a meta-analysis of randomized controlled trials

  2019influential citation
• Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study

  2018cites this paper
• Proangiogenic Effect of Metformin in Endothelial Cells Is via Upregulation of VEGFR1/2 and Their Signaling under Hyperglycemia-Hypoxia

  2018cites this paper
• Effect of metformin on cardiac function in patients with STEMI : a systematic review and meta-analysis

  2018cites this paper
• Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients

  2018cites this paper
• Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC)

  2018cites this paper
• Mitochondrial hexokinase and ischemic sensitivity and metabolism of the heart

  2017cites this paper
• Metformin; a mini-review to its antioxidative and anti-inflammatory properties

  2017cites this paper
• A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction

  2017cites this paper
• Autophagy-Inflammasome Interplay in Heart Failure: A Systematic Review on Basics, Pathways, and Therapeutic Perspectives.

  2017cites this paper
• Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT

  2017cites this paper
• Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.

  2017cites this paper
• High-dose metformin (420mg/kg daily p.o.) increases insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis.

  2017cites this paper
• Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data.

  2017cites this paper
• Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus: A Cardiologist’s View

  2017cites this paper
• Metformina: más allá del control glucémico

  2017cites this paper
• The burden of myocardial infarction

  2017cites this paper
• Targeting the adenosine system to limit ischemia-reperfusion injury : translational research in humans

  2016cites this paper
• Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.

  2016cites this paper
• Metformin as a cellular protector; a synoptic view of modern evidences

  2015cites this paper
• Pharmacological cardioprotection in diabetes

  2015cites this paper
• Restriction of caloric intake is a key to prevention of vascular ageing

  2015cites this paper
• Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial.

  2015cites this paper
• Metformin and preservation of left ventricular function

  2015cites this paper
• Effect ofMetformin on Left Ventricular Function After AcuteMyocardial Infarction in PatientsWithout Diabetes The GIPS-III Randomized Clinical Trial

  2014cites this paper
• Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.

  2014cites this paper
• The Effect of Metformin on Cardiac Fibrosis via Differentiation of Cardiac Fibroblasts

  2014cites this paper
• Response to the Paper by nlR et al. Entitled ‘The Effect of Metformin on Cardiac Fibrosis via Differentiation of Cardiac Fibroblasts'

  2014cites this paper
• The cardiovascular effects of metformin: lost in translation?

  2014influential citation
• Treating Percutaneous Coronary Intervention-Related Myocardial Injury with Metformin

  2013cites this paper